TickerGuard
Buy Day today: Poor (44) Weak market breadth · major macro event coming up
MYGN

Myriad Genetics Inc

Healthcare · Diagnostics & Research

4.00$ -0.2% vs. previous close Closing price · As of: Sep 23, 2026

Statements

Income Statement

Myriad Genetics Inc (MYGN) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Revenue" came in at 825 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement MYGN
Line item 1995 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
6.6 15 23 25 34 45 54 64 57 82 114 157 223 327 363 402 496 613 778 723 741 729 744 851 557 691 678 753 838 825
-1.6 -2.2 -1.9 -0.1 0.7 7.4 11 13 14 20 28 31 32 43 44 47 65 80 109 147 157 171 177 201 178 198 202 236 252 248
8.2 17 25 25 33 38 43 52 43 62 87 126 191 283 318 355 431 534 669 576 583 558 567 650 379 493 476 517 585 577
13 19 23 24 28 34 36 48 51 59 84 101 140 18 22 28 43 54 67 76 71 74 71 86 81 82 85 89 113 107
208 252 327 557 507 538 248 284 276 257
17 30 38 38 45 51 62 79 86 103 132 174 129 157 183 198 251 306 395 442 430 514 445 643 653 684 600 662 673 644
-8.9 -13 -13 -12 -12 -13 -19 -27 -43 -41 -46 -48 62 126 135 158 180 228 274 134 153 44 122 7.6 -195 -191 -124 -145 -88 -68
0.0 0.0 0.0 0.2 0.3 6.0 3.2 12 11 6.6 3.2 2.9 2.8 11
-5.9 -9.2 -9.8 -10 -8.7 -6.6 -13 -24 -41 -40 -38 -35 75 136 141 160 185 233 278 135 156 36 120 7.7 -284 -57 -141 -262 -124 -395
5.9 9.2 9.8 10 8.7 0.6 0.5 0.4 -2.0 -0.8 -7.4 35 0.6 0.2 -11 59 72 86 102 55 39 19 -13 -4.4 -60 -30 -29 1.1 3.8 -29
-5.9 -9.2 -9.8 -10 -8.7 -7.2 -14 -25 -41 -40 -38 -35 48 85 152 101 112 147 176 80 117 17 133 4.6 -224 -27 -112 -263 -127 -366
-7.3 -10 -9.7 -9.2 -8.3 -9.4 -14 -22 -37 -35 -39 -40 70 136 142 165 189 237 288 160 183 91 178 85 -123 12 -85 -197 -60 -331

Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?